Amarin Corp ADR (AMRN) Stock Price, Quote & News

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty p...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 353 0 166 99020

Website: www.amarincorp.com

Address:

One Central Plaza, 5th Floor 36 Dame Street, Dublin 2, Ireland

BullRunner Aug. 25 at 2:25 PM

$AMRN @cevin I see you are still spewing the same BS at the absolute bottom when I was loading up. You win the court jester award for the AMRN board. What happened to going back under 5 after the reverse split? You clowns have no clue what you are doing. Good luck with that short position.

0 · Reply

G550drvr Aug. 25 at 2:03 PM

$AMRN Lets go Amarin, give me some gains like Cognitive Therapeutics. I’ve been here way too long!!

1 · Reply

CEVIN Aug. 25 at 1:25 PM

$AMRN Based on the last few years Data, presentations, late breaking news rarely moves AMRN’s stock price up …..Rising Sales will !….Good luck Monday Manipulators (Pumpers) .

0 · Reply

Bulltrader988 Aug. 25 at 12:16 PM

$AMRN 👃👀 https://www.tipranks.com/news/the-fly/amarin-announces-upcoming-presentations-at-esc-congress-2025-thefly?utm_source=webullapp.com&utm_medium=referral

0 · Reply

Bulltrader988 Aug. 25 at 12:14 PM

$AMRN from PR: "...Moderated Poster Presentations Icosapent Ethyl Reduces CVD Risk in Cardiovascular-Kidney-Metabolic Syndrome: REDUCE-IT CKM - Available August 29th, 16:15 CET -Station 10 – Research Gateway Icosapent Ethyl Reduces Cardiovascular Risk Across Apolipoprotein B and Fasting Triglyceride Rich Lipoprotein Levels Waqas A. Malick, Deepak L. Bhatt, Ph. Gabriel Steg, Michael Miller, Eliot A. Brinton, Steven B. Ketchum, Armando Lira Pineda, Richard L. Dunbar, Jean-Claude Tardif, Fabrice M.A.C. Martens, Christie M. Ballantyne - Available August 30th, 8:15 CET - Station 12 – Research Gateway Eicosapentaenoic Acid (EPA) Inhibited Lipoprotein(a) [Lp(a)] Oxidation and its Effects on Expression of Oxidative Stress and Pro-Inflammatory Proteins in Endothelial Cells Samuel C.R. Sherratt, Peter Libby, Richard L. Dunbar, Deepak L Bhatt, R. Preston Mason - Available August 29th, 13:15 CET - Station 11 – Research Gateway.." 👃👀

0 · Reply

Bulltrader988 Aug. 25 at 12:11 PM

$AMRN "..upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August 29th-September 1st, in Madrid, Spain, where new data will further illuminate the multifaceted cardioprotective effects of icosapent ethyl (IPE).. Oral Presentations Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT Michael Szarek, Deepak L. Bhatt, Michael Miller, Eliot A. Brinton, Jean-Claude Tardif, Christie M. Ballantyne, Steven B. Ketchum, Mandeep R. Mehra, Ph. Gabriel Steg - Available August 30th, 8:15 CET - Sofia (North Convention Centre Eicosapentaenoic Acid (EPA) Modulates Inflammasome Activation in Monocyte-derived Macrophages Isolated from Individuals with and Without Established Atherosclerotic Cardiovascular Disease (ASCVD) Joanna K Ward, Usman Shah, Paul E Squires, Kelvin Lee, Claire E Hills - Available August 31st, 14:30 CET - Science Box 2 – Research Gateway" 👃👀 https://www.stocktitan.net/news/AMRN/new-analyses-from-reduce-it-and-epa-mechanistic-data-to-be-presented-nofuaf9uyy3r.html

0 · Reply

SanDiegoLiving Aug. 25 at 12:05 PM

$AMRN Remember all those ESC congress presentations on IPE I showcased were coming with an INSANELY HEAVY lineup from Dr Bhatt etc in Madrid? Right on cue 🎯 https://www.amarincorp.com/news-and-media/new-analyses-reduce-itr-and-epa-mechanistic-data-be-presented

0 · Reply

CEVIN Aug. 25 at 11:48 AM

$AMRN Good Monday Morning to all our Paid Pumpers, its a great new week and I can see a few have already been busy….Lets see if we can pump, pump, pump it $0.30 today ….

1 · Reply

SanDiegoLiving Aug. 25 at 10:19 AM

$AMRN 📌 POST 1 – MORE COINCIDENCES… OR INTENTIONAL OVERLAP? 🤔 💊 Everyone knows Novartis faces the Entresto patent cliff in 2025. That has been discussed for years. ⏳ But here is what almost nobody caught: the timing of what came next. ➡️ Just two weeks before Amarin licensed full EU Vazkepa rights to Recordati, Novartis quietly shed 427 cardiovascular reps. 🛑 At the very same time, Entresto’s exclusivity expired. Billions in revenue exposed to generics. ⚖️ And here is the kicker: Amarin had secured its EU patent to 2039 in Apr ’24. If the Recordati deal was only about cash or opex savings, it could have been signed then. Instead it took almost 14 months and landed right as Novartis restructured CV. 🤔 Two weeks apart, the moves look coincidental until you overlap them with the Recordati–Novartis relationship I uncovered weeks ago. Then the alignment looks staged. ➡️ Next we look at why Entresto’s LOE leaves Novartis with a $5B hole that demands action…

0 · Reply

SanDiegoLiving Aug. 25 at 10:19 AM

$AMRN 📌 POST 2 – ENTRESTO LOE = A $5 BILLION GAP ⚠️ 💥 Entresto, Novartis’s $5B+ heart drug, lost exclusivity in July ’25. 📉 Generics are inevitable. That is a massive hole in Novartis’s cardiovascular portfolio. ✂️ Just weeks before the cliff hit, Novartis announced it would lay off 427 cardiovascular reps. 📰 The official spin? “Marketing refresh.” “Focus on Leqvio.” “Future Lp(a) launch.” ⚠️ Reality check: Leqvio is still ramping slowly and uptake trending towards a billion+. Pelacarsen is years away and will not generate revenue until 2026+ if outcomes succeed. Neither replaces a $5B cliff in the near term. 📌 Big Pharma does not let cliffs like this sit unaddressed. They reposition resources, cut where revenue collapses, and line up the next anchor. That is why the layoffs matter. It is not just a “refresh” — it is balance-sheet preparation. ➡️ Next we look at why the salesforce cuts in June ’25, paired with Amarin’s EU handoff, are far more than coincidence…

0 · Reply

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Jul 30, 2025, 2:06 PM EDT - 25 days ago

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:00 AM EDT - 26 days ago

Amarin Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:30 AM EDT - 4 weeks ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Jun 24, 2025, 7:05 AM EDT - 2 months ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

May 7, 2025, 11:01 AM EDT - 3 months ago

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:15 PM EDT - 4 months ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 28, 2025, 4:15 PM EDT - 4 months ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 14, 2025, 10:02 AM EDT - 4 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO ALMS CCO ECX HZO NUTX

Apr 9, 2025, 7:30 AM EDT - 4 months ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 7, 2025, 7:30 AM EDT - 5 months ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Mar 19, 2025, 12:45 PM EDT - 5 months ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 7:30 AM EDT - 5 months ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 12, 2025, 10:30 AM EDT - 5 months ago

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:00 AM EST - 6 months ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 19, 2025, 8:30 AM EST - 6 months ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Dec 16, 2024, 7:00 AM EST - 9 months ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 13, 2024, 9:00 AM EST - 9 months ago

Amarin Appoints Peter Fishman Chief Financial Officer

Nov 19, 2024, 7:52 AM EST - 9 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

SLN TERN

Oct 30, 2024, 8:50 PM EDT - 10 months ago

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Jul 31, 2024, 12:28 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 4:15 PM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jun 7, 2024, 7:16 PM EDT - 1 year ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 4, 2024, 7:30 AM EDT - 1 year ago

Amarin Board of Directors Announces CEO Transition

May 28, 2024, 8:15 AM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 6, 2024, 8:00 AM EDT - 1 year ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 1, 2024, 10:43 AM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript

May 1, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Apr 24, 2024, 2:00 PM EDT - 1 year ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 6, 2024, 3:30 PM EDT - 1 year ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 29, 2024, 10:18 AM EST - 1 year ago

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:00 AM EST - 1 year ago

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 15, 2024, 8:00 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Jan 22, 2024, 7:30 AM EST - 1 year ago

Amarin Chairman & CEO Issue Letter to Shareholders

Jan 15, 2024, 3:06 AM EST - 1 year ago

Amarin: Sarissa Is Giving Me Hope Again

Jan 10, 2024, 6:40 PM EST - 1 year ago

Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)

Jan 10, 2024, 7:00 AM EST - 1 year ago

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

Dec 11, 2023, 8:00 AM EST - 1 year ago

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 4, 2023, 4:23 PM EST - 1 year ago

Sarissa Capital Believes Amarin Stock Is Meaningfully Undervalued and Has Increased Its Ownership

Nov 12, 2023, 9:00 AM EST - 1 year ago

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

BullRunner Aug. 25 at 2:25 PM

0 · Reply

G550drvr Aug. 25 at 2:03 PM

$AMRN Lets go Amarin, give me some gains like Cognitive Therapeutics. I’ve been here way too long!!

1 · Reply

CEVIN Aug. 25 at 1:25 PM

$AMRN Based on the last few years Data, presentations, late breaking news rarely moves AMRN’s stock price up …..Rising Sales will !….Good luck Monday Manipulators (Pumpers) .

0 · Reply

Bulltrader988 Aug. 25 at 12:16 PM

$AMRN 👃👀 https://www.tipranks.com/news/the-fly/amarin-announces-upcoming-presentations-at-esc-congress-2025-thefly?utm_source=webullapp.com&utm_medium=referral

0 · Reply

Bulltrader988 Aug. 25 at 12:14 PM

0 · Reply

Bulltrader988 Aug. 25 at 12:11 PM

0 · Reply

SanDiegoLiving Aug. 25 at 12:05 PM

0 · Reply

CEVIN Aug. 25 at 11:48 AM

$AMRN Good Monday Morning to all our Paid Pumpers, its a great new week and I can see a few have already been busy….Lets see if we can pump, pump, pump it $0.30 today ….

1 · Reply

SanDiegoLiving Aug. 25 at 10:19 AM

0 · Reply

SanDiegoLiving Aug. 25 at 10:19 AM

0 · Reply

SanDiegoLiving Aug. 25 at 10:19 AM

$AMRN 📌 POST 3 – WHY SALESFORCE CUTS MATTER IN M&A 🛑 🧹 When two companies shed salesforces in the same window, it is rarely coincidence. It is how balance sheets get “deal ready.” ⚖️ No acquirer wants to inherit duplicate reps. Integration works best if both sides slim down before a transaction. 📅 Jun ’25 → Novartis cuts 427 CV reps 🏢 Jun ’25 → Amarin hands its EU infrastructure to Recordati 💡 The effect? Both companies present leaner P&Ls. For Novartis, synergies look instant and Wall Street sees quicker savings. For Amarin, opex converts to royalties, leaving a cleaner model for any buyer to absorb. 🤔 And because Recordati already has a commercial history with Novartis, the overlap feels less like chance and more like choreography. Two companies trimming at the same time in the same therapeutic area is not a coincidence. It is a signal. ➡️ Now we examine the 14-month delay between Amarin’s patent win and the Recordati signing…

0 · Reply

SanDiegoLiving Aug. 25 at 10:19 AM

$AMRN 📌 POST 4 – THE RECORDATI DELAY: WHY IT MATTERS ⏳ 🪞 Apr ’24 → Amarin locks EU patent until 2039 ✂️ Jun ’25 → Novartis trims reps 📉 Jul ’25 → Entresto LOE hits 🤝 Jun ’25 → Amarin licenses EU rights to Recordati 💰 If licensing was only about cash or $70M in opex relief, the Recordati deal could have been signed right after the patent win. ⏳ Instead, nothing for 14 months. Then suddenly, right as Novartis restructures CV and Entresto’s cliff arrives, the deal closes. That delay is what makes the timing stand out. 🧹 The outcome: Amarin looks leaner, Novartis looks leaner. Both reset their CV businesses in the same window. 🤝 And the chosen partner? Recordati — not random, but one Novartis already works with. That makes the sequence look less like coincidence and more like careful choreography. ➡️ So what does this sequencing really tell us about Amarin’s trajectory and Novartis’s intentions…

0 · Reply

SanDiegoLiving Aug. 25 at 10:19 AM

$AMRN 📌 POST 5 – MY TAKE: SEQUENCING OR RANDOMNESS? 🦅 Most investors focus on U.S. scripts or generics. They miss the structural sequencing that reveals how bigger moves are staged. 📅 Apr ’24 → Amarin patent secured to 2039 ✂️ Jun ’25 → Novartis cuts 427 reps 💊 Jul ’25 → Entresto LOE hits 🤝 Jun ’25 → Amarin signs Recordati — a partner Novartis already works with 🧩 All of it landed within weeks. On the surface, coincidence. But once you overlap it with the Novartis–Recordati ties, it looks staged. 🤔 In my opinion, the Novartis acquisition case is becoming almost impossible to dismiss. The patent, the synchronized salesforce cuts, the Recordati gatekeeper — all point in the same direction. 📌 To me, this is intentional overlap, not randomness. The pieces line up too perfectly & the the direction becomes impossible to ignore. ➡️ And tomorrow I will dive into a very blatant buyout clue that everyone has missed. It has been hiding in plain sight. Stay tuned ⏳

1 · Reply

DoMoreCharity Aug. 25 at 2:45 AM

$AMRN

1 · Reply

declanaidan Aug. 24 at 7:24 PM

$AMRN Given CVS has stated as of 7/1/25 they are providing Vascepa exclusively, no genercs, and now Calpers migrating to CVS as of 1/1/26 as PBM, from United Healthcare, does this render consideration of AG (authorized generic by Amarin) no longer viable? Seems Amarin is making generics a very risky, weak ongoing business as a Vascepa option? I have BC/BS. Generics now not an option. Only Vascepa.

3 · Reply

DoMoreCharity Aug. 24 at 12:00 PM

$AMRN https://www.healthcaredive.com/news/cvs-caremark-calpers-pharmacy-benefits-contract-unitedhealth/753124/

1 · Reply

DoMoreCharity Aug. 24 at 12:10 AM

$AMRN If CVS is taking market share from competitors, so is Vascepa. CVS Caremark: Pharmacy Benefits Effective January 1, 2026, CVS Caremark (CVS) will replace OptumRx as the new pharmacy benefits manager (PBM) for the following CalPERS health plans. https://www.calpers.ca.gov/members/health-benefits/plans-and-rates/cvs-caremark-pharmacy-benefits

1 · Reply

PipDoggie Aug. 23 at 2:07 PM

$AMRN is there any valid reason why I should stop hitting the BUY button?

0 · Reply

PotatoSalad Aug. 23 at 1:31 PM

$AMRN There will be no BO as the company's tangible value is far lower than mgmt's belief.....and the pumpers on this board. This is holding company with one product, limited patent years left, and zero profitability or prospects of profit. Hilarious that mgmt can keep stringing you along and you eat it up. Q3 up next! More of the same decaying sales and time burn as mgmt slowly gobbles up shares and assets to the tune of 20m per year. Best of luck everyone!

2 · Reply

MoneyInc Aug. 23 at 1:43 AM

$AMRN & $GALT both will be bought out or partnerships inside 12 months. Enjoy the ride! Expecting over $100 for both.

1 · Reply

CaptBeer Aug. 22 at 9:59 PM

$AMRN https://www.linkedin.com/posts/amarin-corporation_esccongress2025-cardiology-cvd-activity-7364585248359112704-m76o?utm_medium=ios_app&rcm=ACoAAAdDmycBzT_CwLIulyFqANe8SLMF4KH2Odo&utm_source=social_share_send&utm_campaign=copy_link BEER GOOD $AMRN GOOD

0 · Reply

Novo1 Aug. 22 at 7:59 PM

$AMRN @casinokid1121 now, tell us how you really feel about Denner!🤬😂

0 · Reply

Market Cap	330.90M
Revenue (ttm)	228.61M
Net Income (ttm)	-82.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-35.95%
Debt to Equity Ratio	0.00

Volume	44,600
Avg Vol	112,594
Day's Range	N/A - N/A
Shares Out	20.71M
Stochastic %K	72%
Beta	0.84
Analysts	Hold
Price Target	$11.00